These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33261292)

  • 21. Status of programmed death-ligand 1 expression in sarcomas.
    Park HK; Kim M; Sung M; Lee SE; Kim YJ; Choi YL
    J Transl Med; 2018 Nov; 16(1):303. PubMed ID: 30400799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma.
    Yokoyama S; Miyoshi H; Nakashima K; Shimono J; Hashiguchi T; Mitsuoka M; Takamori S; Akagi Y; Ohshima K
    Clin Cancer Res; 2016 Sep; 22(18):4727-34. PubMed ID: 27166394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy.
    Ni JM; Ni AP
    Chin Med Sci J; 2018 Sep; 33(3):174-182. PubMed ID: 30266108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-L1 expression in sarcomas: An immunohistochemical study and review of the literature.
    Cunningham CR; Dodd L; Esebua M; Layfield LJ
    Ann Diagn Pathol; 2021 Dec; 55():151823. PubMed ID: 34656856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
    Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
    Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
    Sundara YT; Kostine M; Cleven AH; Bovée JV; Schilham MW; Cleton-Jansen AM
    Cancer Immunol Immunother; 2017 Jan; 66(1):119-128. PubMed ID: 27853827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection.
    Scilla KA; Zandberg DP; Bentzen SM; Mainor C; Heath J; Ioffe OB; Cellini AL; Edelman MJ; Riedel DJ; Feliciano JL
    Lung Cancer; 2018 Sep; 123():87-90. PubMed ID: 30089601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors.
    Lu JC; Zeng HY; Sun QM; Meng QN; Huang XY; Zhang PF; Yang X; Peng R; Gao C; Wei CY; Shen YH; Cai JB; Dong RZ; Shi YH; Sun HC; Shi YG; Zhou J; Fan J; Ke AW; Yang LX; Shi GM
    Theranostics; 2019; 9(16):4678-4687. PubMed ID: 31367249
    [No Abstract]   [Full Text] [Related]  

  • 29. PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue - prognostic implications and rationale for immunotherapy.
    Boxberg M; Steiger K; Lenze U; Rechl H; von Eisenhart-Rothe R; Wörtler K; Weichert W; Langer R; Specht K
    Oncoimmunology; 2018; 7(3):e1389366. PubMed ID: 29399389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
    Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
    World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer.
    Hou Y; Nitta H; Wei L; Banks PM; Lustberg M; Wesolowski R; Ramaswamy B; Parwani AV; Li Z
    Breast J; 2018 Nov; 24(6):911-919. PubMed ID: 30230111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Progress in research on tumor immune PD-1/PD-L1 signaling pathway in malignant bone tumors].
    Huang HF; Zhu H; Yang XT; Guo XY; Li SS; Xie Q; Tian XB; Yang Z
    Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):410-414. PubMed ID: 31216825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?
    Hofman P
    Expert Rev Mol Diagn; 2017 Dec; 17(12):1097-1108. PubMed ID: 29069958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy.
    Constantinidou A; Alifieris C; Trafalis DT
    Pharmacol Ther; 2019 Feb; 194():84-106. PubMed ID: 30268773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival.
    Budczies J; Bockmayr M; Denkert C; Klauschen F; Gröschel S; Darb-Esfahani S; Pfarr N; Leichsenring J; Onozato ML; Lennerz JK; Dietel M; Fröhling S; Schirmacher P; Iafrate AJ; Weichert W; Stenzinger A
    Genes Chromosomes Cancer; 2016 Aug; 55(8):626-39. PubMed ID: 27106868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical applications of PD-L1 bioassays for cancer immunotherapy.
    Liu D; Wang S; Bindeman W
    J Hematol Oncol; 2017 May; 10(1):110. PubMed ID: 28514966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma.
    Wu S; Shi X; Sun J; Liu Y; Luo Y; Liang Z; Wang J; Zeng X
    Oncotarget; 2017 Mar; 8(10):16421-16429. PubMed ID: 28145884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT).
    Machado I; López-Guerrero JA; Scotlandi K; Picci P; Llombart-Bosch A
    Virchows Arch; 2018 May; 472(5):815-824. PubMed ID: 29445891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.